Emilie Hestbaek , Johanna Kølle Pedersen , Hanne Lie Kjærstad , Kirsten Rosenkrantz Grage , Lars Vedel Kessing , Sebastian Simonsen , Kamilla Miskowiak
{"title":"边缘型人格障碍和II型双相情感障碍患者的情绪认知:跨诊断和鉴别诊断差异的证据?","authors":"Emilie Hestbaek , Johanna Kølle Pedersen , Hanne Lie Kjærstad , Kirsten Rosenkrantz Grage , Lars Vedel Kessing , Sebastian Simonsen , Kamilla Miskowiak","doi":"10.1016/j.euroneuro.2025.06.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Distinguishing borderline personality disorder (BPD) from bipolar disorder type II (BD-II) is challenging due to overlapping symptoms, often leading to misdiagnosis and suboptimal treatment. This study explored transdiagnostic and diagnostic differences in emotional cognition between patients with BPD, patients with BD-II and healthy controls (HC).</div></div><div><h3>Experimental procedures</h3><div>The sample included 35 patients with BPD, 35 with BD-II in remission, and 35 HC. Emotional cognition was assessed with virtual reality (VR) and the Facial Expression Recognition Task. Participants completed questionnaires regarding occupational and social functioning, quality of life, and childhood trauma. Transdiagnostic differences were explored by comparing each patient group to HC, and diagnostic differences were examined between BPD and BD-II. Regression analyses evaluated the impact of childhood trauma on emotional cognition.</div></div><div><h3>Results</h3><div>Transdiagnostically, patients showed poorer emotion regulation in negative VR scenarios compared to HC, but there were no differences in emotional face processing. Differential diagnostically, patients with BPD were slower at identifying emotional faces than those with BD-II, with trends towards lower accuracy. No significant differences were observed between patients with BPD and patients with BD-II in VR scenarios. Across participants, childhood trauma predicted blunted emotion ratings and slower facial emotion recognition.</div></div><div><h3>Discussion</h3><div>Impaired emotion regulation may serve as a transdiagnostic biomarker for BPD and BD-II, while slower emotion recognition may distinguish BPD from BD-II. Across participants, childhood trauma predicted blunted emotion ratings and slower facial emotion recognition, underscoring its lasting impact.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"98 ","pages":"Pages 13-21"},"PeriodicalIF":6.1000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Emotional cognition in patients with borderline personality disorder and patients with bipolar disorder type II: Evidence for transdiagnostic and differential diagnostic differences?\",\"authors\":\"Emilie Hestbaek , Johanna Kølle Pedersen , Hanne Lie Kjærstad , Kirsten Rosenkrantz Grage , Lars Vedel Kessing , Sebastian Simonsen , Kamilla Miskowiak\",\"doi\":\"10.1016/j.euroneuro.2025.06.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Distinguishing borderline personality disorder (BPD) from bipolar disorder type II (BD-II) is challenging due to overlapping symptoms, often leading to misdiagnosis and suboptimal treatment. This study explored transdiagnostic and diagnostic differences in emotional cognition between patients with BPD, patients with BD-II and healthy controls (HC).</div></div><div><h3>Experimental procedures</h3><div>The sample included 35 patients with BPD, 35 with BD-II in remission, and 35 HC. Emotional cognition was assessed with virtual reality (VR) and the Facial Expression Recognition Task. Participants completed questionnaires regarding occupational and social functioning, quality of life, and childhood trauma. Transdiagnostic differences were explored by comparing each patient group to HC, and diagnostic differences were examined between BPD and BD-II. Regression analyses evaluated the impact of childhood trauma on emotional cognition.</div></div><div><h3>Results</h3><div>Transdiagnostically, patients showed poorer emotion regulation in negative VR scenarios compared to HC, but there were no differences in emotional face processing. Differential diagnostically, patients with BPD were slower at identifying emotional faces than those with BD-II, with trends towards lower accuracy. No significant differences were observed between patients with BPD and patients with BD-II in VR scenarios. Across participants, childhood trauma predicted blunted emotion ratings and slower facial emotion recognition.</div></div><div><h3>Discussion</h3><div>Impaired emotion regulation may serve as a transdiagnostic biomarker for BPD and BD-II, while slower emotion recognition may distinguish BPD from BD-II. Across participants, childhood trauma predicted blunted emotion ratings and slower facial emotion recognition, underscoring its lasting impact.</div></div>\",\"PeriodicalId\":12049,\"journal\":{\"name\":\"European Neuropsychopharmacology\",\"volume\":\"98 \",\"pages\":\"Pages 13-21\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2025-07-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Neuropsychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0924977X25001282\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X25001282","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Emotional cognition in patients with borderline personality disorder and patients with bipolar disorder type II: Evidence for transdiagnostic and differential diagnostic differences?
Introduction
Distinguishing borderline personality disorder (BPD) from bipolar disorder type II (BD-II) is challenging due to overlapping symptoms, often leading to misdiagnosis and suboptimal treatment. This study explored transdiagnostic and diagnostic differences in emotional cognition between patients with BPD, patients with BD-II and healthy controls (HC).
Experimental procedures
The sample included 35 patients with BPD, 35 with BD-II in remission, and 35 HC. Emotional cognition was assessed with virtual reality (VR) and the Facial Expression Recognition Task. Participants completed questionnaires regarding occupational and social functioning, quality of life, and childhood trauma. Transdiagnostic differences were explored by comparing each patient group to HC, and diagnostic differences were examined between BPD and BD-II. Regression analyses evaluated the impact of childhood trauma on emotional cognition.
Results
Transdiagnostically, patients showed poorer emotion regulation in negative VR scenarios compared to HC, but there were no differences in emotional face processing. Differential diagnostically, patients with BPD were slower at identifying emotional faces than those with BD-II, with trends towards lower accuracy. No significant differences were observed between patients with BPD and patients with BD-II in VR scenarios. Across participants, childhood trauma predicted blunted emotion ratings and slower facial emotion recognition.
Discussion
Impaired emotion regulation may serve as a transdiagnostic biomarker for BPD and BD-II, while slower emotion recognition may distinguish BPD from BD-II. Across participants, childhood trauma predicted blunted emotion ratings and slower facial emotion recognition, underscoring its lasting impact.
期刊介绍:
European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.